Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Metabolic and Pathological Response to Treatment With RCT and ImT Before Surgery in Locally Advanced Esophageal and Gastro-esophageal Junction Cancer: ARTemIS-Eso, a Three-level, Open-label, Phase I-II Study

Next Previous
X
Search
Trial Profile

Assessment of Metabolic and Pathological Response to Treatment With RCT and ImT Before Surgery in Locally Advanced Esophageal and Gastro-esophageal Junction Cancer: ARTemIS-Eso, a Three-level, Open-label, Phase I-II Study

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Monalizumab (Primary) ; Fluorouracil; Oxaliplatin
  • Indications Adenocarcinoma; Gastrointestinal cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms ARTemIS-Eso

    • Most Recent Events

    • 18 Dec 2017 Planned End Date changed from 1 Mar 2021 to 11 Dec 2017.
    • 18 Dec 2017 Planned primary completion date changed from 1 Mar 2019 to 11 Dec 2017.
    • 18 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top